Miniatura

Fitxers

596954.pdf (1.36 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2011-06-23

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/135519

Exemestane for breast-cancer prevention in postmenopausal women

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJMoa1103507

Resum

Background: tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer. Methods: in a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors: 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured. Results: a total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval [CI], 0.18 to 0.70; P=0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P=0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P=0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed. Conclusions: exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.

Matèries

Testosterona, Ús terapèutic, Càncer de mama

Matèries (anglès)

Testosterone, Therapeutic use, Breast cancer

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citació

GOSS, Paul e., INGLE, James n., ALÉS MARTÍNEZ, José enrique, CHEUNG, Angela m., CHLEBOWSKI, Rowan t., WACTAWSKI-WENDE, Jean, MCTIERNAN, Anne, ROBBINS, John, JOHNSON, Karen c., MARTIN, Lisa w., WINQUIST, Eric, SARTO, Gloria e., GARBER, Judy, FABIAN, Carol j., PUJOL, Pascal, MAUNSELL, Elizabeth, FARMER, Patricia, GELMON, Karen a., TU, Dongsheng, RICHARDSON, Harriet, NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. _New England Journal of Medicine_. 2011. Vol. 364, núm. 25, pàgs. 2381-2391. [consulta: 20 de gener de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/135519]

Exportar metadades

JSON - METS

Compartir registre